Navigation Links
Nerviano Medical Sciences Invited by EORTC-NCI-AACR to Present the State-of-the-Art of Aurora
Date:10/23/2008

NERVIANO, Italy, October 23 /PRNewswire/ --

- First Responses in Solid Tumours Reported.

Aurora inhibitors play a key role in cell duplication and are implicated in both the onset and progression of numerous types of tumour. A lecture focusing on Aurora kinase inhibitors will be presented today by Dr. Bernard Laffranchi during the 20th EORTC-NCI-AACR Symposium "Molecular Targets and Cancer Therapeutics" organised from 21st to 24th October 2008 in Geneva. Dr Laffranchi, Director Clinical Research of Nerviano Medical Sciences, the largest R&D cancer drug stand alone company in Europe (http://www.nervianoms.com) has been invited to give a presentation on the state-of-the-art of Aurora kinase inhibitors, providing a comprehensive summary of ongoing clinical studies being performed on this molecular target to which increasing attention is being paid by the experts.

"Nerviano Medical Sciences (NMS) has been chosen by these prestigious scientific societies in view of the fact that the Italian centre has a recognized leadership in research & development of Aurora inhibitors," explains Francesco Colotta, Research & Development Director at NMS. Indeed, compounds capable of inhibiting activity of this kinase family and displaying anti-tumour efficacy in a wide range of solid and blood cancers models were first identified at Nerviano. Moreover, emphasises Dr. Colotta, the Aurora inhibitors discovered at Nerviano were the first to be evaluated in patients and to undergo clinical development.

"This symposium will be organised in a particularly pragmatic fashion and provides a wide-ranging overview of all data collected with regard to future treatment of patients," underlines Dr. Colotta. "Preliminary results of human clinical Phase II trials with Aurora inhibitors carried out by NMS are underway," continues Dr. Colotta. The product at the most advanced stage of development is PHA 739358, a selective inhibitor of the entire Aurora kinase family (A, B and C), which, terminated Phase I studies and is now undergoing clinical Phase II trials in solid tumours and blood cancers at some of the most widely acknowledged international clinics: Erasmus Medical Center, Rotterdam, Policlinico Gemelli, Rome, Gustave Roussy, Villejuif, France, University of California, Los Angeles (UCLA) and University of California, San Francisco (UCSF) Fox Chase Cancer Center, Philadelphia, to name some of the most important. "This low molecular weight compound is inhibiting growth of tumour cells by interacting with mitosis during cell proliferation for which Aurora kinases are essential."

During the EORTC-NCI-AACR Symposium a recently identified biomarker used to assess PHA 739358 activity will also be presented by Dr. Bernard Laffranchi, NMS. The marker, Histone H3, is phosphorylated by Aurora kinases and is strongly reduced following treatment with the compound. "This phenomenon was initially highlighted in experimental tumour models and was recently confirmed by findings obtained from patient biopsies", explains Laffranchi. A decreased phosphorylation of Histone H3 in patients treated with PHA 739358 supports this hypothesis whereby the anti-cancer activity exerted by the compound is mediated through inhibition of Aurora kinases.

"Results obtained to date in humans reveal that PHA 739358 is a molecule with a good tolerability profile and promising hints of activity were seen," states Dr. Colotta. In Phase I trials, PHA 739358 was administered intravenously to patients with advanced and progressive solid tumours. In 20% of patients treated the disease stabilised, half of which for a period exceeding six months in subjects affected by cancer of the kidney, oesophagus, ovary, colon or non-small cell lung cancer (NSCLC). Toxicity, ranged from slight to moderate, was reversible and easily manageable from a clinical point of view. "In Phase I trials a partial response to treatment with this molecule was also observed in a patient with small cell lung cancer (SCLC) who, upon treatment, displayed a 77% reduction of one cancer lesion and resolution of a second one," concludes Dr. Colotta.

Abstract no: 243, presented 10.15 hrs on Thursday 23 October, Plenary session 5
Information: http://www.nervianoms.com

Nerviano Medical Sciences

Maria D'Acquino

Phone +39-0331-581013 - mobile +39-335-18-63-052

Email maria.dacquino@nervianoms.com


'/>"/>
SOURCE Nerviano Medical Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General
2. TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
3. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
4. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
5. Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children
6. Resurgent Health and Medical Announces That Childrens Hospitals and Clinics of Minnesota has Ordered 25 CleanTech Automated Handwashing Systems
7. International Medical Corps Matched with Top 25 American Express Members Project, Saving the Lives of Malnourished Children
8. Concentric Medical to Sponsor Randomized Trial
9. MedNet Solutions to Sponsor and Exhibit at the 2008 Advanced Medical Technology Association Conference in Washington, D.C.
10. KGI Professor Ian Phillips Awarded Defense Grants for Medical Combat Research
11. 7 Health Ventures Invests in Tulip Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 On Wednesday, February 22, 2017, ... out of nine sectors finished the trading sessions in green, ... closing. Major US indices were also mixed at the close ... 5,860.63, slightly down by 0.09%; the Dow Jones Industrial Average ... 500 closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com ...
(Date:2/23/2017)... 2017 ML Capital Group, Inc. (USOTC: MLCG) ... Highlife Tours , a Colorado -based cannabis ... Puration, Inc. (USOTC: PURA) to enter Colorado,s ... Colorado Highlife Tours acquisition announced today is intended to accelerate MLCG,s ... ...
(Date:2/23/2017)... Wash. and VANCOUVER, British Columbia ... (NASDAQ: OGXI ) today announced its year ... In January 2017, OncoGenex, and Achieve Life ... that they have entered into a definitive merger agreement ... transaction. Upon completion of the proposed merger, Achieve,s stockholders ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which ... participating in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates ... a website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... content provider for the National Institute for Health and Care Excellence ... organizations in the National Health Service (NHS) to search, order and purchase medical ...
(Date:2/23/2017)... ... 23, 2017 , ... Current Meditation , a new ... throughout the U.S. starting this spring. Current Meditation focuses on “meditation for the ... Current Meditation will be the first meditation concept in the U.S. offering franchising ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist ... today with a new Indiegogo campaign . Individuals are now able to contribute ... Los Angeles area, either as a participating patient or through an Indiegogo donation. The ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... and lobby of a new healthcare contact center in Georgia, PENETRON Specialty Products ... of the nation’s largest healthcare systems recently invested $51 million to purchase and ...
Breaking Medicine News(10 mins):